BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3703746)

  • 1. Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the rat.
    Neubauer BL; Bemis KG; Best KL; Goode RL; Merriman RL; Smith GF; Tanzer LR; Hoover DM
    Prostate; 1986; 8(3):265-76. PubMed ID: 3703746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
    Neubauer BL; Best KL; Counts DF; Goode RL; Hoover DM; Jones CD; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
    Prostate; 1995 Oct; 27(4):220-9. PubMed ID: 7479389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.
    Neubauer BL; Merriman RL; Best KL; Goode RL; Sarosdy MF; Tanzer LR; Howbert JJ
    J Urol; 1992 Feb; 147(2):500-4. PubMed ID: 1732631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
    Neubauer BL; Bemis KG; Best KL; Goode RL; Hoover DM; Smith GF; Tanzer LR; Merriman RL
    J Urol; 1986 Jan; 135(1):163-6. PubMed ID: 3941458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
    Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
    Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
    Neubauer BL; McNulty AM; Chedid M; Chen K; Goode RL; Johnson MA; Jones CD; Krishnan V; Lynch R; Osborne HE; Graff JR
    Cancer Res; 2003 Sep; 63(18):6056-62. PubMed ID: 14522935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
    Desai D; Sinha I; Null K; Wolter W; Suckow MA; King T; Amin S; Sinha R
    Int J Cancer; 2010 Jul; 127(1):230-8. PubMed ID: 19918950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats.
    Hodde JP; Suckow MA; Wolter WR; Hiles MC
    J Surg Res; 2004 Aug; 120(2):189-94. PubMed ID: 15234212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAIII prostate tumors express prostate specific antigen (PSA) in Lobund-Wistar rats.
    Suckow MA; Wheeler J; Yan M
    Can J Vet Res; 2009 Jan; 73(1):39-41. PubMed ID: 19337394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
    Heinrich JE; Pollard M; Wolter WA; Liang Z; Song H; Rosen ED; Suckow MA
    Cancer Immunol Immunother; 2007 May; 56(5):725-30. PubMed ID: 16953436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer.
    Pollard HB; Levine MA; Eidelman O; Pollard M
    In Vivo; 2010; 24(3):249-55. PubMed ID: 20554995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of an extracellular matrix material as a vaccine carrier and adjuvant.
    Suckow MA; Hall P; Wolter W; Sailes V; Hiles MC
    Anticancer Res; 2008; 28(5A):2529-34. PubMed ID: 19035274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer.
    Sinha I; Null K; Wolter W; Suckow MA; King T; Pinto JT; Sinha R
    Int J Cancer; 2012 Mar; 130(6):1430-9. PubMed ID: 21500193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantable metastasizing prostate adenocarcinomas in rats.
    Pollard M; Luckert PH
    J Natl Cancer Inst; 1975 Mar; 54(3):643-9. PubMed ID: 1123852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastasis-enhancing effect of heparin and its relationship to a lipoprotein factor.
    Chan SY; Pollard M
    J Natl Cancer Inst; 1980 May; 64(5):1121-5. PubMed ID: 6929014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Conditioned Extracellular Matrix as a Tissue-engineered Tumor Matrisome for Prostate Cancer and Melanoma Immunotherapy.
    Suckow MA; Hiles MC
    Anticancer Res; 2023 Jan; 43(1):335-341. PubMed ID: 36585187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer in a Sprague-Dawley rat.
    Pollard M; Luckert PH
    Prostate; 1985; 6(4):389-93. PubMed ID: 4088952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors in prostate cancer metastasis.
    Geldof AA; Rao BR
    Anticancer Res; 1990; 10(5A):1303-6. PubMed ID: 2241106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
    Chang CJ; Ghosh PK; Hu YF; Brueggemeier RW; Lin YC
    Res Commun Chem Pathol Pharmacol; 1993 Mar; 79(3):293-312. PubMed ID: 8480076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dimethylsulfoxide on the proliferation and glycosaminoglycan synthesis of rat prostate adenocarcinoma cells (PAIII) in vitro: isolation and characterization of DMSO-resistant cells.
    Kaneski CR; Constantopoulos G; Brady RO
    Prostate; 1991; 18(1):47-58. PubMed ID: 1987579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.